Study design and population
CAD, triple-vessel coronary artery disease, cardiovascular disease
HEART, CARDIOVASCULAR DISEASE, CAD
The current study was a single-center randomized, controlled trial. symptomatic patients diagnosed with triple-vessel coronary artery disease (CAD) by angiography and were scheduled for isolated CABG surgery at Tehran Heart Center between April 2018 and April 2020 were included in the study. Patients with single-vessel CAD and/or other concomitant cardiac surgery, such as valve replacement, aorta reconstruction, or other additional cardiovascular disease necessitating concomitant surgery, were excluded. All medical records were retrieved from the Cardiac Surgery Database of the Tehran Heart Center. The study protocol was approved by Tehran Heart Center ethical board (IR.TUMS.THC.REC.1399.005) and was registered at the Iranian clinical trial registry (IRCT20190120042428N1). All patients signed written informed consent upon enrollment. This study was designed and performed under the declaration of Helsinki and its updates.